1896928397
Endocrine Deep Dives

Advertise on podcast: Endocrine Deep Dives

Rating
★★★★★
5
from
2 reviews
This podcast has
142 episodes
Language
English
Explicit
No
Date created
2026/06/15
Latest episode
2026/11/13
Average duration
23 min.
Release period
2 days

Description

The Endocrine Deep Dive covers advanced topics in endocrinology. Utilizing AI-driven synthetic audio discussions from my own study notes, each episode breaks down complex endocrine concepts. Comprehensive Legal & Medical Disclaimer: Endocrine Deep Dives and all associated content, materials, and digital assets are produced strictly for informational and educational purposes only. The program is intended solely for healthcare providers, medical fellows, residents, and students as a supplement to their professional training. No Physician-Patient Relationship: Listening to this podcast, accessing show notes, or interacting with the platform does not establish a physician-patient, pharmacist-patient, or any other formal professional-client relationship between the host and any listener or patient. Not Medical Advice: The content does not constitute individualized medical advice, clinical diagnosis, or treatment recommendations. Patients and members of the general public must never use this content to guide personal healthcare decisions and must always consult a qualified, licensed physician or healthcare provider for any medical concerns. Clinical Responsibility: Healthcare professionals listening to this program must exercise their own independent clinical judgment. The host's interpretations, study notes, and opinions reflect personal perspectives on literature and do not set an official standard of care. Clinicians bear sole responsibility for verifying all pharmacological dosing, diagnostic criteria, and treatment protocols against official institutional guidelines, current primary literature, and individual patient presentation. Limitation of Liability: The host, creators, and associated entities disclaim any and all liability for direct, indirect, incidental, or consequential damages resulting from the use, misuse, application, or interpretation of any information presented in this podcast. Reliance on any data or opinion provided is solely at the listener's own risk.

Unlock Endocrine Deep Dives podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Endocrine Deep Dives podcast


Nuanced Hyperthyroidism Workup
2026/11/13
Differentiating thyrotoxicosis etiologies requires moving beyond suppressed TSH to evaluate free T3 to free T4 ratios, TRAb titers, and radioactive iodine uptake kinetics. We break down distinguishing high-uptake states like Graves disease and toxic adenomas from destructive thyroiditis, the utility of Doppler ultrasound, and targeted management strategies across antithyroid drug selection, radioactive iodine, and surgical indications.
The Oral Overnight Metyrapone Test
2026/11/12
The overnight metyrapone test interrogates hypothalamic-pituitary-adrenal reserve via 11-beta-hydroxylase blockade, circumventing cosyntropin false-negatives in acute corticotroph injury where adrenocortical atrophy is absent. Interpretation demands sequential analysis: post-dose cortisol below 5 ug/dL confirms enzyme inhibition, while 11-deoxycortisol above 7 ug/dL verifies reserve. Levels between 7 to 10 ug/dL require Bayesian pretest calibration. Testing established insufficiency risks precipitating adrenal crisis.
Thyroid Radioactive Iodine Uptake Patterns
2026/11/11
Radioactive iodine uptake differentiates de novo hyperthyroidism from destructive or factitious thyrotoxicosis. Diffusely elevated tracer accumulation confirms Graves disease driven by thyrotropin-receptor antibodies, whereas focal autonomy denotes toxic adenoma or toxic multinodular goiter with extranodular suppression. Conversely, suppressed or absent uptake indicates destructive thyroiditis, exogenous hormone exposure, or recent iodine contamination, shifting clinical management from thionamides toward symptomatic beta-blockade.
Adrenergic Symptoms Differentials
2026/11/10
This episode reviews the differential diagnosis of paroxysmal adrenergic symptoms, contrasting sympathoadrenal hyperreactivity with catecholamine-secreting neuroendocrine tumors. We analyze the diagnostic utility and pre-test confounding factors of plasma versus fractionated urinary metanephrines, evaluate concurrent features of thyrotoxicosis, carcinoid syndrome, and mast cell activation, and outline evidence-based alpha-blockade protocols prior to surgical or medical intervention.
POTS and endocrine mimics
2026/11/09
This episode evaluates postural orthostatic tachycardia syndrome, exploring neuroendocrine and autonomic dysregulation, including hyperadrenergic phenotypes and volume depletion. We examine diagnostic tilt-table criteria, the crucial exclusion of primary endocrine mimics such as pheochromocytoma and adrenal insufficiency, and evidence-based management strategies spanning fludrocortisone, nonselective beta-blockers, alpha-1 agonists, and structured physical reconditioning.
Subclinical Hyperthyroidism
2026/11/06
This episode examines subclinical hyperthyroidism, characterized by suppressed serum TSH alongside normal free thyroxine and triiodothyronine. We analyze etiology differentiation between autonomous nodular disease and Graves disease, risk stratification for atrial fibrillation and accelerated bone loss, and guideline thresholds for initiating antithyroid pharmacotherapy or definitive ablation in older adults and postmenopausal patients.
Elevated Cortisol: False Positive vs CS?
2026/11/05
Pretest probability dictates the entire diagnostic workflow for Cushing syndrome by guiding appropriate patient selection for screening and preventing false positives from incidentalomas or physiological hypercortisolism. Because diagnostic tests carry distinct false-positive rates when applied to low-risk populations, initial biochemical evaluation must be strictly reserved for patients with recognizable clinical stigmata or progressive multisystem manifestations. Quantifying clinical probability prevents the diagnostic cascade of unindicated testing, ensuring that abnormal screening results reflect true autonomous cortisol excess rather than benign physiological mimics or stress-induced alterations.
Primary Aldosteronism: Diagnostic Nuances
2026/11/04
Screening for primary aldosteronism requires measuring the aldosterone-to-renin ratio under standardized conditions, accounting for interfering antihypertensives and hypokalemia. Diagnosis hinges on non-suppressible autonomous aldosterone secretion via confirmatory suppression testing. Once confirmed, adrenal protocol cross-sectional imaging and adrenal vein sampling are essential to reliably differentiate unilateral surgically curable adenomas from bilateral idiopathic adrenal hyperplasia prior to targeted intervention.
Familial Partial Lipodystrophy
2026/11/03
Familial partial lipodystrophy mutations causing progressive subcutaneous fat loss from the extremities and trunk with paradoxical fat accumulation in the face and neck. This redistribution precipitates severe insulin resistance, hypertriglyceridemia, and premature cardiovascular disease. Diagnosis relies on physical examination recognizing characteristic fat loss patterns, genetic testing, and metabolic profiling. Management focuses on aggressive metabolic optimization, lifestyle modification, and targeted therapies for dyslipidemia and glycemic control to mitigate long-term cardiovascular and hepatic sequelae.
Emil Theodor Kocher
2026/11/02
Emil Theodor Kocher revolutionized endocrine surgery by developing meticulous, sterile, and bloodless thyroidectomy techniques. His standardized operative methods reduced surgical mortality from nearly forty percent to under one percent. Kocher's precise documentation of cachexia strumipriva fundamentally delineated thyroid physiological function and postoperative myxedema, establishing the foundations of modern surgical endocrinology and safe neck exploration.
Calcitonin
2026/10/30
Calcitonin, secreted by thyroid parafollicular C cells, acts as a physiological antagonist to parathyroid hormone by suppressing osteoclastic bone resorption and renal tubular calcium reabsorption. While minor in routine adult calcium homeostasis, serum calcitonin serves as an indispensable diagnostic and post-thyroidectomy surveillance biomarker for medullary thyroid carcinoma, directly correlating with tumor burden, staging, and systemic progression.
Multiple Endocrine Neoplasia Type 1
2026/10/29
Multiple endocrine neoplasia type 1 arises from inactivating MEN1 tumor suppressor mutations, causing loss of menin function. Clinical manifestations classically feature primary hyperparathyroidism due to multiglandular hyperplasia, enteropancreatic neuroendocrine tumors, and anterior pituitary adenomas. Management prioritizes subtotal parathyroidectomy with transcervical thymectomy, specialized biochemical surveillance, and aggressive multi-phase imaging to detect malignant functional pancreatic lesions early.
Crinecerfont for Steroid Reduction in CAH
2026/10/28
This episode evaluates crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, for classic congenital adrenal hyperplasia. By blocking pituitary ACTH secretion independently of glucocorticoid feedback, crinecerfont reduces adrenal androgen excess, including androstenedione. This mechanism permits significant supraphysiologic glucocorticoid dose reduction toward physiologic replacement levels, mitigating long-term iatrogenic metabolic and skeletal complications while preserving adrenal control.
Billing Code CGM/95251
2026/10/27
Analysis and interpretation of continuous glucose monitoring data requiring at least seventy-two hours of sensor wear. This physician service focuses on evaluating glycemic variability, time in range, and nocturnal hypoglycemia to refine therapy. Documentation requires a dedicated written interpretation addressing glycemic trends and actionable management changes, distinct from sensor placement and calibration procedures.
Billing Code G2211
2026/10/27
Explore the clinical implementation of add-on code G2211 for longitudinal endocrinology outpatient care. We analyze Centers for Medicare and Medicaid Services documentation requirements, medical decision-making thresholds, and audit vulnerabilities when capturing complex chronic disease management. Key takeaways include differentiating routine evaluation and management encounters from sustained, comprehensive continuity and structuring electronic health record workflows to ensure defensible reimbursement.

Podcast reviews

Read Endocrine Deep Dives podcast reviews


5 out of 5
2 reviews
★★★★★
Big diabetes 2026/07/04
Brilliant
Dr Gill is brilliant, absolutely loved his podcasts, have them all downloaded and love listening on my commutes
check all reviews on apple podcasts

Podcast sponsorship advertising

Start advertising on Endocrine Deep Dives relevant audience podcasts


What do you want to promote?